Dr. Pramod K. Srivastava is the Eversource Energy Chair in Experimental Oncology, the director of the Center Center for Immunotherapy of Cancer and Infectious Diseases, and the director of the Carole and Ray Neag Comprehensive Cancer Center at UConn Health. He is a professor in the department of immunology at the University of Connecticut School of Medicine.
Dr. Srivastava is renowned for his discovery of proteins that allow the immune system to eliminate tumors, and the development of the first cancer vaccine to be approved anywhere in the world―Oncophage® was approved by Russia in 2008, and is currently being tested in clinical trials elsewhere, including here in the United States. In recognition of his accomplishments, he was elected into the National Academy of Inventors.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Srivastava serves on the CLIP Grant Review Committee and is a member of CRI’s global clinical investigator network.
We must not worry about translation. We should focus on doing good fundamental science; how to make big discoveries and make sure they’re real. All good science gets applied.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.